{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:29:10Z","timestamp":1793104150832,"version":"4.5.0"},"reference-count":46,"publisher":"Japan Atherosclerosis Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2007]]},"DOI":"10.5551\/jat.14.99","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T13:45:32Z","timestamp":1308231932000},"page":"99-108","source":"Crossref","is-referenced-by-count":140,"title":["Zetia: Inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to Reduce Intestinal Cholesterol Absorption and Treat Hyperlipidemia"],"prefix":"10.5551","volume":"14","author":[{"given":"Harry R","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Cardiovascular\/Metabolic Disease Schering-Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico P","family":"Veltri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular\/Metabolic Disease Schering-Plough Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) van Heek M, France C, Compton DS, Mcleod RL, Yumibe NP, Alton KB, Sybertz EJ, and Davis HR: In-vivo mechanism-based discovery of a potent cholesterol absorption inhibitor (SCH58235) through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther, 1997; 283: 157-163","DOI":"10.1016\/S0022-3565(24)36992-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Clader J: The discovery of ezetimibe: A view from outside the receptor. J Med Chem, 2004; 47: 1-9","DOI":"10.1021\/jm030283g"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) van Heek M, France C, Compton D, Hoos L, Alton K, Sybertz E, and Davis HR: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacology, 2000; 129: 1748-1754","DOI":"10.1038\/sj.bjp.0703235"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) van Heek M, Compton DS, and Davis HR: The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. European J Pharm, 2001; 415: 79-84","DOI":"10.1016\/S0014-2999(01)00825-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) van Heek M, Farley C, Compton DS, Hoos L, and Davis HR: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. British J Pharm, 2001; 134: 409-417","DOI":"10.1038\/sj.bjp.0704260"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ballantyne CM: Ezetimibe: efficacy and safety in clinical trials. Eur Heart J, 2002; 4(Suppl J): J9-J18","DOI":"10.1016\/S1520-765X(02)90077-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, and Cayen MN: Disposition of the selective cho-lesterol absorption inhibitor ezetimibe in healthy male sub-jects. Drug Metab Dispos, 2003; 30: 430-437","DOI":"10.1124\/dmd.30.4.430"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Kosoglou T, Statkevich P, Johnson-Levonas OA, Paolini JF, Bergman AJ, and Alton KB: Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet, 2005; 44: 467-494","DOI":"10.2165\/00003088-200544050-00002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Davis HR: Ezetimibe: First in a new class of cholesterol absorption inhibitors. International Congress Series, Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium, Edited by Matsuzawa Y, Kita T, Nagai R, and Teramoto T, Volume 1262, pp 243-246, Else-vier BV, Amsterdam, 2004","DOI":"10.1016\/j.ics.2003.11.026"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Sudhop T, Lutjohann D, Kodal A, Tribble D, Shah S, Perevozskaya I, and von Bergmann K: Inhibition of cholesterol absorption by ezetimibe in humans. Circulation, 2002; 106: 1943-1948","DOI":"10.1161\/01.CIR.0000034044.95911.DC"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Altmann SW, Davis HR, Yao X, Laverty M, Compton DS, Zhu L, Crona JH, Caplen MA, Hoos LM, Tetzloff G, Priestley T, Burnett DA, Strader CD, and Graziano MP: The identification of intestinal Scavenger Receptor Class B, Type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochimica et Biophysica Acta, 2002; 1580: 77-93","DOI":"10.1016\/S1388-1981(01)00190-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Altmann SW, Davis HR, Zhu L, Yao X, Hoos LM, Tetzloff G, Iyer SN, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, and Graziano MP: Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004; 303: 1201-1204","DOI":"10.1126\/science.1093131"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Iyer SN, Yao X, Crona JH, Hoos LM, Tetzloff G, Davis HR, Graziano MP, and Altmann SW: Characterization of the putative and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochimica et Biophysica Acta, 2005; 1722: 282-292","DOI":"10.1016\/j.bbagen.2004.12.021"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Davis HR, Zhu L, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer S, Lam M, Lund EG, Detmers PA, Graz-iano MP, and Altmann SW: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole body cholesterol homeostasis. J Biol Chem, 2004; 279: 33486-33592","DOI":"10.1074\/jbc.M405817200"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Salen G, von Bergmann K, Lutjohann D, Kwitervich P, Kane J, Patel SB, Musliner T, Stein P, Musser B, and Multicenter Sitosterolemia Study Group: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation, 2004; 109: 966-971","DOI":"10.1161\/01.CIR.0000116766.31036.03"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Salen G, Starc T, Sisk CM, and Patel SB: Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology, 2006; 130: 1853-1857","DOI":"10.1053\/j.gastro.2006.02.027"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Davis HR, Compton D, Hoos L, and Tetzloff G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in apoE knockout mice. Arterioscler Thromb Vasc Biol, 2001; 21: 2032-2038","DOI":"10.1161\/hq1201.100260"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Davis HR, Hoos LM, Tetzloff G, Maguire M, Zhu L, Graziano MP, and Altmann SW: Deficency of Niemann-Pick C1 Like 1 (NPC1L1) prevents atherosclerosis in apoE -\/- mice. Arterioscler Thromb Vasc Biol, 2007; 27: 841-849","DOI":"10.1161\/01.ATV.0000257627.40486.46"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, Graziano MP, Hughes M, MacIntyre DE, Ogawa A, O'Neill KA, Iyer SN, Shevell DE, Smith MM, Tang YS, Ujjainwalla F, Altmann SW, Chapman KT, and Thornberry NA: The target of ezetimibe is Niemann-Pick C1 Like 1 (NPC1L1). Proc Natl Acad Sci USA, 2005; 102: 8132-8137","DOI":"10.1073\/pnas.0500269102"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Hawes BE, O'Neill KA, Yao X, Crona JH, Davis HR, Graziano MP, and Altmann SW: In vivo responsiveness to ezetimibe correlates with NPC1L1 binding affinity: Comparison of multiple species NPC1L1 orthologs. Mol Pharmacol, 2007; 71: 19-29","DOI":"10.1124\/mol.106.027896"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hegele RA, Guy J, Ban MR, and Wang J: NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis, 2005; 4: 16-20","DOI":"10.1186\/1476-511X-4-16"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, Monks SA, Severino ME, Deutsch P, Palmisano J, Sachs AB, Bayne ML, Plump AS, and Schadt EE: Sequence vari-ation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics, 2005; 86: 648-656","DOI":"10.1016\/j.ygeno.2005.08.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, and Hobbs HH: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA, 2006; 7: 103: 1810-1825","DOI":"10.1073\/pnas.0508483103"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Huff MW, Pollex RL, and Hegele RA: NPC1L1: Evolut-ion from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol, 2006; 26: 2433-2438","DOI":"10.1161\/01.ATV.0000245791.53245.ee"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Clarenbach JJ, Reber M, Lutjohann D, von Bergmann K, and Sudhop T: The lipid-lowering effect of ezetimibe in pure vegetarians. J Lipid Res, 2006; 47: 2820-2824","DOI":"10.1194\/jlr.P600009-JLR200"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, and Ezetimibe Study Gr-oup: Efficacy and safety of a potent new selective choleste-rol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol, 2002; 90: 1092-1097","DOI":"10.1016\/S0002-9149(02)02798-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP, and Ezetimibe Study Group: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with pri-mary hypercholesterolemia. Eur Heart J, 2003; 24: 729-741","DOI":"10.1016\/S0195-668X(02)00807-2"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, and Veltri EP: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical stu-dies. Int J Clin Pract, 2003; 57: 363-368","DOI":"10.1111\/j.1742-1241.2003.tb10508.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, and Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc, 2005; 80: 587-595","DOI":"10.4065\/80.5.587"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, and Veltri EP: Ezetimibe coa-dministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol, 2002; 40: 2125-2134","DOI":"10.1016\/S0735-1097(02)02610-4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP, and Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-bl-ind trial. Circulation, 2003; 107: 2409-2415","DOI":"10.1161\/01.CIR.0000068312.21969.C8"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri EP, and Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol, 2003; 91: 418-424","DOI":"10.1016\/S0002-9149(02)03236-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri E, and Ezetimibe Study Group: Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-bl-ind trial. Eur Heart J, 2003; 24: 717-728","DOI":"10.1016\/S0195-668X(02)00803-5"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R, Mitchel Y, and Veltri E: Effects of ezetimibe coadminist-ered with simvastatin on C-reactive protein in a large coh-ort of hypercholesterolemic patients. Atherosclerosis, 2005; 179: 361-367","DOI":"10.1016\/j.atherosclerosis.2004.10.021"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Goldberg AC, Sapre A, Liu J, Capece R, and Mitchel YB: Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc, 2004; 79: 620-629","DOI":"10.4065\/79.5.620"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR, and Ezetimibe Study Group: A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the eze-timibe\/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther, 2004; 26: 1758-1773","DOI":"10.1016\/j.clinthera.2004.11.016"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Ballantyne CM, Blazing MA, King TR, Brady WE, and Palmisano J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol, 2004; 93: 1487-1494","DOI":"10.1016\/j.amjcard.2004.02.060"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Ballantyne CM, Abate N, Yuan Z, King TR, and Palmisano J: Dose-comparison study of the combination of ezetimibe and simvastatin(Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Ator-vastatin(VYVA) study. Am Heart J, 2005; 149: 464-473","DOI":"10.1016\/j.ahj.2004.11.023"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, and Tershakovec AM: Eze-timibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc, 2006; 81: 1579-1588","DOI":"10.4065\/81.12.1579"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, and Tershakovec AM: Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin, 2006; 22: 2041-2053","DOI":"10.1185\/030079906X132721"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E, and EXPLORER Study Investigators: Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol, 2007; 99: 673-680","DOI":"10.1016\/j.amjcard.2006.10.022"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Farnier M, Volpe M, Massaad R, Davies MJ, and Allen C: Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol, 2005; 102: 327-332","DOI":"10.1016\/j.ijcard.2005.01.022"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, and Gumbiner B: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol, 2006; 47: 1584-1587","DOI":"10.1016\/j.jacc.2005.11.072"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Farnier M, Roth E, Gil-Extremera B, Mendez GF, Macdonell G, Hamlin C, Perevozskaya I, Davies MJ, Kush D, Mitchel YB, and Ezetimibe\/Simvastatin \uff0b Fenofibrate Study Group: Efficacy and safety of the coadministration of ezetimibe\/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J, 2007; 153: 335 e1-8","DOI":"10.1016\/j.ahj.2006.10.031"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Kastelein JJ, Sager PT, de Groot E, and Veltri E: Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J, 2005; 149: 234-239","DOI":"10.1016\/j.ahj.2004.06.024"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Rossebo AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, and Willenheimer R: Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol, 2007; 99: 970-973","DOI":"10.1016\/j.amjcard.2006.10.064"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/14\/3\/14_3_99\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:57:06Z","timestamp":1741244226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/14\/3\/14_3_99\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.14.99","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007]]}}}